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Primary biliary cirrhosis (PBC) is characterized by antimitochondrial autoantibodies (AMAs) in patients’ sera and histologically
by chronic nonsuppurative destructive cholangitis in small bile ducts, eventually followed by extensive bile duct loss and biliary
cirrhosis. The autoimmune-mediated pathogenesis of bile duct lesions, including the signiﬁcance of AMAs, triggers of the
autoimmune process, and so on remain unclear. We have reported that cellular senescence in biliary epithelial cells (BECs) may
be involved in bile duct lesions and that autophagy may precede the process of biliary epithelial senescence in PBC. Interestingly,
BECs in damaged bile ducts show characteristicsof cellular senescence and autophagy in PBC. A suspected causative factor of
biliary epithelial senescence is oxidative stress. Furthermore, senescent BECs may modulate the microenvironment around bile
ducts by expressing various chemokines and cytokines called senescence-associated secretory phenotypes and contribute to the
pathogenesis in PBC.
1.Introduction
Primary biliary cirrhosis (PBC) is a chronic, progressive cho-
lestatic liver disease that aﬀects usually middle-aged women
and occasionally leads to liver failure and liver transplanta-
tion [1–5]. Autoimmune pathogenesis is suggested in PBC
[1–4], because PBC is serologically characterized by a high
titerofserumantimitochondrialautoantibodies(AMAs)and
by an increased level of immunoglobulin M (IgM). PBC-
speciﬁc antinuclear antibodies (ANAs), such as anti-gp210
are also detected in some patients [1, 2, 6–9]. AMAs are
present in about 95% of patients with PBC, with disease
speciﬁcity close to 100%. An inner lipoyl domain of the
E2-component of pyruvate dehydrogenase (PDC-E2) and
other 2-oxo-acid dehydrogenases is a major epitope for
both B-cell and CD4 and CD8 T-cell response [9–12]. PBC
is characterized histologically by the cholangitis of small
bile ducts (chronic nonsuppurative destructive cholangitis;
CNSDC), eventually followed by the extensive loss of small
bile ducts and biliary cirrhosis [2, 3, 13]. Therefore, a major
target of autoimmune-mediated injury has been thought to
be biliary epithelial cells (BECs) in PBC.
There has been considerable progress in elucidating the
immunopathological features [9–12], genetic factors [14–
17], and environmental factors such as infectious agents
and xenobiotics [5, 18–20] in the pathogenesis of PBC. The
most accepted hypothesis states that PBC results from a
combination of multiple genetic factors (susceptible genetic
background) and superimposed environmental triggers. In
this scenario, adaptive, both humoral and cellular (CD4 and
CD8 T cells), and innate immunity have been proposed
as coplayers in immune-mediated liver damage; however,
the etiology and pathogenesis of PBC remain unclear.
In particular, the signiﬁcance of AMAs and autoantigen-
speciﬁc T-cell response in the pathogenesis of bile duct
lesions remainsunknown. Onehypothesis foraBEC-speciﬁc
autoimmune reaction is a unique property of apoptosis in
BECs, in which there is exposure of autoantigen to the
eﬀectors of the immune system [4, 21–23].
We have recently reported that cellular senescence and
autophagy may be involved in bile duct lesions in PBC
[24–28]. These two cellular processes may be related to
autoimmunemechanismsuchasAMAsandtheautoantigen-
speciﬁc Tcelland play a role tocauseautoimmune-mediated2 International Journal of Hepatology
bile duct lesions in PBC. Recent studies have disclosed
that autophagy plays an important role in innate immune
responsesandpossiblyautoimmunity[29–31].Furthermore,
it is plausible that senescent BECs modulate microenviron-
ment around bile duct by expressing senescence-associated
secretory phenotypes (SASPs) including various chemokines
andcontributetothepathogenesisofbileductlesionsinPBC
[32]. In this paper, we will focus on cellular senescence and
autophagy in BECs in PBC and their possible involvement in
the progression of diseases.
2.CellularSenescenceinthe DamagedSmall
BileDuctsinPBC
2.1. What Is Cellular Senescence? Cellular senescence is
deﬁned as a condition in which a cell no longer has the
ability to proliferate. Senescent cells remain metabolically
active, even though they are irreversibly arrested at the
G1 phase of the cell cycle and do not respond to various
external stimuli. Cellular senescence can be triggered by a
number of cellular stresses including telomere dysfunction.
Other causes include oxidative stress, nontelomeric DNA
damage, epigenetic derepression of the INK4a/ARF locus,
and oncogenic activation [33]. Several features, such as
increased activity of senescence-associated β-galactosidase
(SA-β-gal) (Figure 1), shortened telomeres, increased
expression of p16INK4 and p21WAF1/CIP, and histological
changes (Figure 1), are known to characterize cellular
senescence [34–36]. Cellular senescence is a potent tumor
suppression mechanism as well as apoptosis [33, 37].
Senescent cells are also seen in aged or damaged tissues,
and they may decline tissue regeneration capacity with age
[33]. Cellular senescence may play a role in limiting wound-
healing responses following tissue damage [38]. Recent
studies have disclosed that cellular senescence is involved
in the pathophysiology of various chronic liver diseases,
including chronic viral hepatitis and hepatocarcinogenesis
[24, 26, 27, 38–44].
2.2. Bile Duct Lesion in PBC. “Chronic nonsuppurative de-
structive cholangitis (CNSDC)” is a characteristic bile duct
lesion in PBC (Figure 1(a))[ 2, 3, 13, 45]. Bile duct damage
in early PBC mainly aﬀects the septal and larger interlobular
bile ducts, while the smaller interlobular ducts remain intact
until later. The BECs in the aﬀected bile ducts show irregular
shape and arrangement with inﬁltration of mononuclear
cells. The presence of epithelioid granuloma around the
aﬀected bile duct is also a feature of PBC. Bile duct loss even-
tuallyprogressesandchroniccholestasisdevelopes gradually.
Hepatitisactivityofvaryingdegreesisfrequentlyimposedon
the liver at the same time. We proposed a new histological
staging and grading system of PBC for comprehensive analy-
sis of the histological progression of PBC (staging) toward
extensive bile duct loss, chronic cholestasis and cirrhosis,
and also the immune-mediated necroinﬂammatory activity
of small bile ducts and hepatocytes [46].
2.3. Biliary Epithelial Senescence in Damaged Small Bile
Ducts in PBC. BECs in damaged small bile ducts in PBC
show senescent features, such as the expression of SA-β-gal
and the increased expression of p16INK4a and p21WAF1/Cip1
(Figure 1)[ 24–27]. Furthermore, a signiﬁcant decrease in
telomere length was observed in BECs in the damaged
small bile ducts and bile ductules in PBC compared with
normal-looking bile ducts and bile ductules in PBC, chronic
viral hepatitis, and normal livers, when examined using
quantitative ﬂuorescence in situ hybridization [25]. γH2AX
DNA damage foci were detected in BECs in damaged small
bile ducts and bile ductules in PBC but were absent in
BECs in control livers. The expression of p16INK4a and
p21WAF1/Cip1 increased corresponding to telomere shortening
and γH2AX DNA damage foci in the damaged small bile
ducts in PBC [25]. Taken together, telomere shortening and
the accumulation of DNA damage coinciding with increased
expressions of p16INK4a and p21WAF1/Cip1 in the damaged bile
ducts characterize biliary cellular senescence and may play
a role in subsequent progressive bile duct loss in PBC [24–
27]. Interestingly, chronic liver allograft rejection, which is
characterized by bile duct loss similar to PBC, also shows
similar biliary epithelial senescence [24, 40].
2.4. How Does Cellular Senescence Result in Bile Duct Loss?
The exact mechanism how cellular senescence of BECs cause
bile duct loss in PBC is not clear. Cellular senescence is
supposed to impair tissue integrity and cause persistent
inﬂammation [47] .A f t e rc e l l u l a rs e n e s c e n c eo c c u r si n
injured BECs, these senescent cells are thought to remain
in situ and not to be replaced by normal cells, although
nonsenescent BECs proliferate in response to injury [48].
Therefore, it is plausible that the senescent BECs are prone
to further injuries, accentuating inﬂammation by SASP,
which is likely to be followed by bile duct loss in PBC.
The fate of senescent BECs remains to be clariﬁed: whether
senescent BECs are removed by necrosis, apoptosis, or
anoikis. Another possibility is that bile duct loss may be
due to impaired function of hepatic stem/progenitor cells in
PBC. Cellular senescence is also seen in bile ductular cells
in a ductular reaction (DR), which is thought to harbor
hepatic stem/progenitor cells in PBC [24, 25]. The impaired
proliferation of hepatic stem/progenitor cells may fail to
replace the damaged BECs in small bile ducts, subsequently
cause bile duct loss.
2.5. Oxidative Stress Is a Potential Factor Inducing Cellular
Senescence. Cellularsenescencecanbetriggeredbyanumber
of cellular stresses, including telomere dysfunction, oxidative
stress, nontelomeric DNA damage, epigenetic derepression
of the INK4a/ARF locus, and oncogenic stress [33, 39].
The possible association of oxidative stress is suggested
to be involved in the pathogenesis of cellular senescence
in PBC [24, 26, 27]. For example, p21WAF1/Cip1,a c t i -
vated/phosphorylated ATM, and an oxidative stress marker,
8-OHdG, were frequently and extensively coexpressed in
the nuclei of CNSDC in PBC, and their expressions wereInternational Journal of Hepatology 3
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Figure 1:BiliaryepithelialsenescenceinPBC.BECsinsmallbileductsinvolvedinchronicnonsuppurativedestructivecholangitis(CNSDC)
show histological features of senescence, such as cytoplasmic eosinophilia, cellular and nuclear enlargement, and uneven nuclear spacing (a).
SA-β-gal activity is detected in BECs in PBC (b). Senescent markers, p21WAF1/Cip1 and p16INK4a, were expressed in BECs in damaged small
bile ducts in PBC (c) and (d). Immunostaining for p21WAF1/Cip1 and p16INK4a. Original magniﬁcation: ×400.
correlated [26]. Cell culture study suggests that oxidative
stress and proinﬂammatory cytokines, such as IFN-β,I F N - γ,
and TNF-α, which induce ROS generation, activate the
ATM/p53/p21WAF1/Cip1 pathway,followedbybiliaryepithelial
senescence [49]. The expression of polycomb group protein
Bmi1issigniﬁcantlydecreasedindamagedbileductsinPBC,
coordinating with the increased expression of p16INK4a [27].
The decreased expression of Bmi1 is induced by oxidative
stress, followed by the increased expression of p16INK4a in
cultured BECs [27]. Since an antioxidant, N-acetylcysteine
can inhibit cellular senescence induced by oxidative stress
and proinﬂammatory cytokines [49], antioxidants may have
therapeutic implications in PBC.
3.CellularSenescence inDuctularReaction
(DR)inPBC
DR is a reactive lesion at the portal tract interface composed
of increased bile ductules with an accompanying complex
of stromal and inﬂammatory cells [50]. DR is thought to
harbor hepatic stem/progenitor cells [50]. We investigated
the pathological signiﬁcance of DR in chronic liver diseases,
including PBC, with respect to cellular senescence [24,
25, 51]. The expression of senescence-associated markers
(p16INK4a and p21WAF1/Cip1) was frequently expressed in
ductular cells in the advanced stage of chronic liver diseases,
especially in PBC. Double immunostaining disclosed that
neural cell adhesion molecules (NCAM) were frequently
coexpressed in ductular cells showing senescence-associated
markers (p16INK4a and p21WAF1/Cip1)a n dc e l lc y c l eG 1 - p h a s e
marker (cyclin D) (Figure 2)[ 51]. These ﬁndings suggest
that DR is heterogeneous in cell kinetics and the expression
of NCAM and that some ductular cells in DR in chronic
liver diseases were at G1 arrest and undergoing cellular
senescence. Such senescent cells may be involved in the
progression of ﬁbrosis of these diseases, particularly in PBC
[51]. This study raises the possibility that NCAM can be
used as a cellular senescent marker developing in DRs.
Furthermore, our recent study revealed that CCL2 expressed
by senescent BECs can induce the cell migration of hepatic
stellate cells (HSCs), which may play a role in the periportal
ﬁbrosis in chronic advanced liver diseases [52].
4.Autophagy inDamagedSmall
BileDuctsinPBC
4.1. What Is Autophagy? Autophagy, or cellular selfdigestion,
is a cellular pathway that results from various cellular4 International Journal of Hepatology
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Figure 2: Double immunostaining for senescence markers (p16INK4a or p21WAF1/Cip1) and cell cycle markers (G1-phase, cyclin D; S-phase,
cyclin A) (red) and NCAM (green) in PBC, stage 4. (a), (c) The expression of senescent markers p16INK4a and p21WAF1/Cip1 is seen in NCAM-
positive ductular cells (arrows) in PBC, stage 4. (b), (d) Most NCAM-positive ductular cells (arrows) express cyclin D, whereas there is no
cyclin A expression in DRs in PBC, stage 4. Original magniﬁcation ×400.
stresses, such as nutrient starvation, anoxia, and activation
of the endoplasmic reticulum stress pathway [53, 54]. Three
types of autophagy, macroautophagy, microautophagy, and
chaperone-mediated autophagy, have been classiﬁed, and
macroautophagy is the major type [53–55]. It is becom-
ing evident that macroautophagy (hereafter referred to as
autophagy) is important for development, diﬀerentiation,
survival, homeostasis, and also many pathological processes.
Autophagy occurs physiologically at low basal levels in
cells to perform homeostatic functions such as protein
and organelle turnover. It is rapidly upregulated through
an inhibition of mammalian target of rapamycin (mTOR)
when cells need to generate intracellular nutrients and
energy, for example, in starvation [53–55]. Microtubule-
associated protein-light chain 3β (LC3), a homologue of
autophagy-related protein 8 (Apg8p), which is essential for
autophagy and associated with autophagosome membranes
after processing, is a widely used marker of autophagy [56,
57].
4.2. Cellular Senescence, Apoptosis, and Autophagy. An
appropriate cellular stress response is critical for maintaining
tissueintegrityandfunctionandforpreventingdiseases[58].
Cellular senescence, apoptosis, and autophagy are cellular
responses to stress, correlating with each other [58]. Cellular
stresses cause adaptation, repair, autophagy, apoptosis, or
cellular senescence in cells [58]. These cell fate decisions are
criticaltodealingwiththeemergenceofdamagedandpoten-
tially dangerous cells that can cause cancer. Interestingly, a
recent study disclosed that autophagy is induced during and
facilitates the process of senescence [56]. Cellular senescence
can be a failsafe program against a variety of cellular insults,
as well as apoptosis. Cellular senescence is a typical delayed
stress response involving multiple eﬀector mechanism, in
contrast,cytotoxicsignalsconvergetoacommonmechanism
in apoptosis. With the onset of cellular senescence cells can
remain viable within tissues for long periods; resistance to
apoptosis is a characteristics of senescent cells [41, 59].
4.3. Biliary Epithelial Autophagy in PBC. We have reported
the upregulated autophagy in the damaged small bile ducts
along with cellular senescence in PBC [28]( Figure 3). LC3, a
commonly used marker of autophagy, was characteristically
expressed in cytoplasmic vesicles in bile duct lesions in PBC
[28].AutophagicmarkerLC3wascoexpressedwithsenescent
markers p21WAF1/Cip1 and p16INK4a in damaged bile ducts
in PBC [28]. The inhibition of autophagy reduced stress-
induced cellular senescence in cultured cells with stress [28].
This ﬁnding is in consistent with a recent study in which
the involvement of autophagy is reported in the process ofInternational Journal of Hepatology 5
senescence [56]. Taken together, biliary epithelial autophagy
may mediate the process of biliary epithelial senescence in
bile duct lesions in PBC and it may be involved in the
pathogenesis of bile duct lesions in PBC.
4.4. Autophagy and Autoimmune-Mediated Processes in PBC.
An unsolved problem is how autophagy and cellular senes-
cence are involved in the autoimmune-mediated processes
such as AMA and other PBC-related autoantigens in PBC.
Regardingapoptosis,ithasbeenreportedthatBECsmanifest
unique features during apoptosis and that the combination
ofAMAandBECsapoptoticbodies(apotopes)couldactivate
innate immune response with involvement of some inﬂam-
matory cytokines [21]. This study provides a mechanism
for the biliary speciﬁcity of PBC and the involvement of
AMA in autoimmune pathogenesis [21]. Recent studies
reveal a crucial role for the autophagy pathway and proteins
in immunity and inﬂammation [29–31]. The autophagy
pathway and autophagy proteins may function as a central
fulcrum that balances the beneﬁcial and harmful eﬀects
of the host response to infection and other immunologi-
cal stimuli [31]. Autophagy proteins function in adaptive
immunity, including in the development and homeostasis
of the immune system and in antigen presentation [31].
Furthermore, autophagy proteins play a role in both the
activation and inactivation of innate immune signaling [30,
31]. On the contrary, it is demonstrated that autophagy is
regulated by immune-signaling molecules, such as toll-like
receptors (TLRs), IFN-γ,a n dN F - κB[ 30, 31].
The dysfunctional autophagy related to the regulation
of immunity may contribute also to chronic inﬂamma-
tory diseases and probably autoimmune diseases. A well-
characterized link is between mutations in autophagy reg-
ulators and Crohn’s disease, a chronic inﬂammatory bowel
disease, in which autophagy proteins, ATG16L1, NOD2, and
IRGM are reported as susceptibility genes [60]. Abnormal
autophagy/autophagy protein may also result in inﬂam-
matory autoimmune disease, although not yet proven.
Autophagy-related processing of self-proteins provides a
source of immunostimulatory molecules and autoantigens,
that is, by MHC-class II presentation of cytosolic antigens
and control of T-cell homeostasis [61–63]. It is of interest
that genomewide association studies (GWAS) have linked
severalsinglenucleotidepolymorphisms(SNPs)inATG5,an
autophagy protein, to systemic lupus erythematosus (SLE)
susceptibility [64, 65]. SLE is a representative multisystem
autoimmune disease characterized by an enormous array of
autoantibodies such as ANAs and autoimmune responses
against self-antigens generated from dying cells. To date, it
is unclear how such SNPs aﬀect the expression level and
function of ATG5. Interestingly, in mice, the lack of ATG5-
dependent negative thymic selection generates autoimmu-
nity and multiorgan inﬂammation [66]. The autoimmunity
and inﬂammation associated with SLE may be caused by
loss of other ATG5-dependent eﬀects, such as regulation of
IFN and proinﬂammatory cytokine secretion, clearance of
dying cells [67], and dendritic cell antigen presentation [68].
Taken together, a link between SLE pathogenesis and ATG5
mutation or mutation of other autophagy genes is plausible,
although not yet proven.
Similar to SLE, it is possible that a dysfunctional
autophagic process of BECs may play a role in autoimmune
pathogenesis,forexample,theimmunetolerancebreakdown
of autoantigens, in PBC, although this is only speculative at
thismoment.RecentgeneticstudiesofPBCincluding GWAS
identiﬁed, in a reproducible fashion, genetic associations
between PBC and human leukocyte antigen as well as
polymorphisms in the genes encoding IL-12 α-chain and IL-
12receptorβ-chain[14,15].GWASalsoidentiﬁedinterferon
regulatory factor 5 (IRF5)-transportin 3 (TNPO3), 17q12-
21, MMEL1, and SPIB as new PBC susceptibility loci
[14, 15]. These immune-related genes may be associated
with dysfunction autophagy in PBC, although there have
been no identiﬁed autophagy proteins such as ATG5 and
ATG16L1 as PBC susceptibility genes. In fact, IRF5 plays
a key role in the innate immunity response as part of
the TLR signaling pathway and mediates apoptosis induced
by tumor necrosis factor-related apoptosis-inducing ligand
[69, 70]. Interestingly, IRF5 loci have been reported as
associated loci with several autoimmune diseases including
SLE and Sjogren’s syndrome [71, 72]. Therefore, IRF5 might
be related to dysfunctional autophagy in PBC, although not
yet reported.
5.Senescence-AssociatedSecretory
Phenotypes(SASPs)inPBC
5.1. What Are SASPs? An increasing body of work described
the change in the cellular secretosome in senescent cells.
Senescent cells play an important role in modulating the
microenvironment by secreting biological active molecules,
senescence-associated secretory phenotypes (SASPs). SASPs
include diverse proinﬂammatory factors such as cytokines
(IL-6, IL-1 and so on) and chemokines (CXCL8/IL-8,
CCL2/monocyte chemotactic protein-1 (MCP)-1) and so
on), growth factors and proﬁbrogenic factors [73–77].
Previous studies have shown that BECs express a number
of proﬁbrogenic proinﬂammatory and chemotactic factors
(e.g., IL-1, IL-6, CXCL8/IL-8, and CCL2/MCP-1) [78–81].
These factors can attract and activate inﬂammatory cells and
also stellate cell lineage in humans with biliary disorders and
in animal models of biliary ﬁbrosis. Taken together, these
cytokines and chemokines previously reported in PBC may
belong to SASPs [73–77].
5.2. SASPs May Play a Role in the Pathogenesis of PBC.
The upregulation of several cytokines and chemokines in
damaged bile ducts in PBC has been reported [79, 80, 82],
and these factors may represent SASPs, as described above
[73–77]. We have recently reported that the involvement
of senescent BECs in modulation of the inﬂammatory
microenvironment around aﬀected small bile ducts in PBC
(Figure 4)[ 32]. In this study, we have shown that the
expression of CCL2 and CX3CL1 was signiﬁcantly higher
in BECs in inﬂamed and damaged small bile ducts in
PBC, than in noninﬂamed bile ducts and control livers6 International Journal of Hepatology
PBC, non- nﬂammed i
(a)
PBC, inﬂamed
(b)
Figure 3: Biliary epithelial autophagy in PBC. (a) The expression of autophagy marker LC3 was not observed in BECs in noninﬂammed bile
ducts (arrow) in PBC. (b) The expression of autophagy marker LC3 was detected in intracytoplasmic vesicles (arrows) in BECs involved in
inﬂamed and damaged small bile ducts in PBC. Immunostaining for LC3. Original magniﬁcation, ×400 (inset, ×1000).
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Figure 4: Increased expression of CCL2 in inﬂamed and damaged bile ducts in PBC. (a) The expression of CCL2 was absent or faint in
biliary epithelial cells (BECs) in the small bile duct (arrow) in normal liver (top). CCL2 was extensively expressed in the membrane and
cytoplasm of damaged and senescent BECs (arrows) in the early stage of PBC (bottom). Immunostaining for CCL2. Original magniﬁcation,
×400. (b) The expression of CCL2 was signiﬁcantly more frequent and intense in inﬂamed small bile ducts in PBC, when compared with
noninﬂamed small bile ducts in PBC and small bile ducts in control livers (P<. 01). CVH: chronic viral hepatitis; NASH: nonalcoholic
steatohepatitis; EBO: extrahepatic biliary obstruction; NL: normal liver.
(Figure 4). The expression of CCL2 and CX3CL1 was
colocalized with the expression of senescent markers in
damaged bile ducts in PBC [32]. In culture study, senescent
BECs induced by cellular stresses expressed a signiﬁcantly
higher level of chemokines. Furthermore, senescent BECs
signiﬁcantly accelerated the migration of RAW264.7 cells,
and neutralizing antibodies against CCL2 and CX3CL1
blocked in part the migration induced by senescent BECs
[32]. These ﬁndings suggest that senescent BECs may play
an important role in the pathogenesis of bile duct lesion
in PBC by the accentuated inﬂammatory microenvironment
through recruiting monocytes and other inﬂammatory cells
via SASP (Figure 5). SASPs in senescent BECs in PBC may
contributetoactivationoftheinnateimmunesystemaround
injured bile ducts. Furthermore, it raises the possibility
that once biliary senescence develops, the change in the
tissue microenvironment wrought by the SASP may induce
senescence of surrounding BECs another types of cells in
appositive feedback loop (Figure 5).
The mechanisms that initiate and maintain SASPs have
not been clariﬁed, so far [33, 73–75]. It is plausible that
these stresses may induce SASPs via a common mechanism
in the senescent state, because various cellular stresses, such
as oxidative stress and serum deprivation, induce SASPs in
senescent BECs [32].International Journal of Hepatology 7
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Figure 5: Possible regulation of microenvironment by senescent
BECs expressing SASPs in PBC. Senescent BECs may function in
modulation of the inﬂammatory microenvironment by recruiting
monocytes and possibly other inﬂammatory cells by secreting
chemokines and cytokines as SASPs. Senescent BECs may also
participate in the induction of senescence in surrounding cells and
progression of ﬁbrosis via SASPs.
6. Summary
PBC is thought to result from a combination of multiple
genetic factors and superimposed environmental triggers
andapparentlybelongstothe“complexdisease”categorylike
most polygenic autoimmune diseases. Even though mito-
chondrial autoantigens and B-cell and T-cell autoepitopes
have been well characterized in PBC, the pathogenesis of
characteristic bile duct lesion and the exact role of AMA
still remain to be elucidated. In this paper, we focused
on a possible involvement of two novel cellular processes,
autophagy and cellular senescence in BECs in bile duct
lesions in PBC. Autophagy is expected to be a promising
cellular mechanism involved in the autoimmune mechanism
together with apoptosis. Cellular senescence may play a role
in the immunopathology of BECs by expressing SASPs in
PBC. Further studies are needed to disclose the autoimmune
pathogenesis of PBC.
Acknowledgment
This study was supported in part by a Grant-in Aid for Sci-
entiﬁcResearch(C)fromtheMinistryofEducation,Culture,
Sports and Science and Technology of Japan (18590325 and
2590366).
References
[1] M. E. Gershwin, I. R. Mackay, A. Sturgess, and R. L.
Coppel, “Identiﬁcation and speciﬁcity of a cDNA encoding
the 70kd mitochondrial antigen recognized in primary biliary
cirrhosis,” Journal of Immunology, vol. 138, no. 10, pp. 3525–
3531, 1987.
[2] M. M. Kaplan, “Medical progress: primary biliary cirrhosis,”
New England Journal of Medicine, vol. 335, no. 21, pp. 1570–
1580, 1996.
[3] B. Portmann and Y. Nakanuma, “Diseases of the bile ducts,” in
Pathology of the Liver,R .M a c S w e e n ,A .B u r t ,B .C .P o r t m a n n ,
K. Ishak, P. Scheuer, and P. Anthony, Eds., pp. 435–506,
Churchill Livingstone, London, UK, 4th edition, 2001.
[4] M. E. Gershwin and I. R. Mackay, “The causes of primary
biliary cirrhosis: convenient and inconvenient truths,” Hepa-
tology, vol. 47, no. 2, pp. 737–745, 2008.
[5] M. Sasaki, A. Ansari, and N. Pumford, “Comparative
immunoreactivity of anti-triﬂuoroacetyl (TFA) antibody and
anti-lipoic acid antibody in primary biliary cirrhosis: search-
ing for a mimic,” Journal of Autoimmunity, vol. 15, no. 1, pp.
51–60, 2000.
[6] J. Van de Water, M. E. Gershwin, P. Leung, A. Ansari, and
R. L. Coppel, “The autoepitope of the 74-kD mitochondrial
autoantigen of primary biliary cirrhosis corresponds to the
functional site of dihydrolipoamide acetyltransferase,” Journal
ofExperimentalMedicine,vol.167,no.6,pp.1791–1799,1988.
[7] P.S.C.Leung,D.T.Chuang,andR.M.Wynn,“Autoantibodies
to BCOADC-E2 in patients with primary biliary cirrhosis
recognize a conformational epitope,” Hepatology, vol. 22, no.
2, pp. 505–513, 1995.
[8] C. D. Surh, R. Coppel, and M. E. Gershwin, “Struc-
tural requirement for autoreactivity on human pyruvate
dehydrogenase-E2, the major autoantigen of primary biliary
cirrhosis. Implication for a conformational autoepitope,”
Journal of Immunology, vol. 144, no. 9, pp. 3367–3374, 1990.
[9] S. P. M. Fussey, J. R. Guest, O. F. W. James, M. F. Bassendine,
and S. J. Yeaman, “Identiﬁcation and analysis of the major M2
autoantigens in primary biliary cirrhosis,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 85, no. 22, pp. 8654–8658, 1988.
[10] H. Kita, Z. X. Lian, and J. Van De Water, “Identiﬁcation
of HLA-A2-restricted CD8 cytotoxic T cell responses in
primary biliary cirrhosis: T cell activation is augmented by
immunecomplexescross-presentedbydendriticcells,”Journal
of Experimental Medicine, vol. 195, no. 1, pp. 113–123, 2002.
[11] S.Shimoda,J.VandeWater,andA.Ansari,“Identiﬁcationand
precursorfrequencyanalysisofacommonTcellepitopemotif
in mitochondrial autoantigens in primary biliary cirrhosis,”
Journal of Clinical Investigation, vol. 102, no. 10, pp. 1831–
1840, 1998.
[12] T. Kamihira, S. Shimoda, and K. Harada, “Distinct costimula-
tion dependent and independent autoreactive T-cell clones in
primarybiliarycirrhosis,” Gastroenterology,vol.125,no.5,pp.
1379–1387, 2003.
[13] Y. Nakanuma and G. Ohta, “Histometric and serial section
observations of the intrahepatic bile ducts in primary biliary
cirrhosis,” Gastroenterology, vol. 76, no. 6, pp. 1326–1332,
1979.
[14] X. Liu, P. Invernizzi, and Y. Lu, “Genome-wide meta-analyses
identify three loci associated with primary biliary cirrhosis,”
Nature Genetics, vol. 42, no. 8, pp. 658–660, 2010.
[15] G. M. Hirschﬁeld, X. Liu, C. Xu et al., “Primary biliary
cirrhosis associated with HLA, IL12A, and IL12RB2 variants,”
New England Journal of Medicine, vol. 360, no. 24, pp. 2544–
2555, 2009.
[16] P. Invernizzi, M. Miozzo, and P. M. Battezzati, “Frequency
of monosomy X in women with primary biliary cirrhosis,”
Lancet, vol. 363, no. 9408, pp. 533–535, 2004.
[17] P. Invernizzi and M. E. Gershwin, “The genetics of human
autoimmune disease,” Journal of Autoimmunity,v o l .3 3 ,n o .3 -
4, pp. 290–299, 2009.
[18] M. E. Gershwin, C. Selmi, and H. J. Worman, “Risk factors
and comorbidities in primary biliary cirrhosis: a controlled
interview-based study of 1032 patients,” Hepatology, vol. 42,
no. 5, pp. 1194–1202, 2005.8 International Journal of Hepatology
[19] C. Selmi, D. L. Balkwill, and P. Invernizzi, “Patients with
primarybiliarycirrhosisreactagainstaubiquitousxenobiotic-
metabolizing bacterium,” Hepatology, vol. 38, no. 5, pp. 1250–
1257, 2003.
[20] S. A. Long, C. Quan, and J. Van de Water, “Immunoreactivity
of organic mimeotopes of the E2 component of pyruvate
dehydrogenase: connecting xenobiotics with primary biliary
cirrhosis,” Journal of Immunology, vol. 167, no. 5, pp. 2956–
2963, 2001.
[21] A. Lleo, C. L. Bowlus, and G. X. Yang, “Biliary apotopes
and anti-mitochondrial antibodies activate innate immune
responsesinprimarybiliarycirrhosis,”Hepatology,vol.52,no.
3, pp. 987–996, 2010.
[22] A. Lleo, C. Selmi, and P. Invernizzi, “Apotopes and the biliary
speciﬁcityofprimarybiliarycirrhosis,”Hepatology,vol.49,no.
3, pp. 871–879, 2009.
[23] J. A. Odin, R. C. Huebert, L. Casciola-Rosen, N. F. LaRusso,
and A. Rosen, “Bcl-2-dependent oxidation of pyruvate
dehydrogenase-E2, a primary biliary cirrhosis autoantigen,
during apoptosis,” Journal of Clinical Investigation, vol. 108,
no. 2, pp. 223–232, 2001.
[24] M. Sasaki, H. Ikeda, H. Haga, T. Manabe, and Y. Nakanuma,
“Frequent cellular senescence in small bile ducts in primary
biliary cirrhosis: a possible role in bile duct loss,” Journal of
Pathology, vol. 205, no. 4, pp. 451–459, 2005.
[25] M. Sasaki, H. Ikeda, J. Yamaguchi, S. Nakada, and Y.
Nakanuma, “Telomere shortening in the damaged small bile
ducts in primary biliary cirrhosis reﬂects ongoing cellular
senescence,” Hepatology, vol. 48, no. 1, pp. 186–195, 2008.
[26] M. Sasaki, H. Ikeda, and Y. Nakanuma, “Activation of
ATM signaling pathway is involved in oxidative stress-
induced expression of mito-inhibitory p21 in chronic non-
suppurative destructive cholangitis in primary biliary cirrho-
sis:animmunohistochemicalstudy,”JournalofAutoimmunity,
vol. 31, no. 1, pp. 73–78, 2008.
[27] M. Sasaki, H. Ikeda, Y. Sato, and Y. Nakanuma, “Decreased
expression of Bmi1 is closely associated with cellular senes-
cence in small bile ducts in primary biliary cirrhosis,”
American Journal of Pathology, vol. 169, no. 3, pp. 831–845,
2006.
[28] M. Sasaki, M. Miyakoshi, Y. Sato, and Y. Nakanuma,
“Autophagy mediates the process of cellular senescence char-
acterizing bile duct damages in primary biliary cirrhosis,”
Laboratory Investigation, vol. 90, no. 6, pp. 835–843, 2010.
[29] K. Cadwell, K. K. Patel, and N. S. Maloney, “Virus-plus-
susceptibility gene interaction determines Crohn’s disease
gene Atg16L1 phenotypes in intestine,” Cell, vol. 141, no. 7,
pp. 1135–1145, 2010.
[30] T. Saitoh and S. Akira, “Regulation of innate immune
responses by autophagy-related proteins,” J o u r n a lo fC e l l
Biology, vol. 189, no. 6, pp. 925–935, 2010.
[31] B. Levine, N. Mizushima, and H. W. Virgin, “Autophagy in
immunity and inﬂammation,” Nature, vol. 469, no. 7330, pp.
323–335, 2011.
[32] M. Sasaki, M. Miyakoshi, Y. Sato, and Y. Nakanuma, “Modu-
lation of the microenvironment by senescent biliary epithelial
cells may be involved in the pathogenesis of primary biliary
cirrhosis,” Journal of Hepatology, vol. 53, no. 2, pp. 318–325,
2010.
[33] M. Collado, M. A. Blasco, and M. Serrano, “Cellular senes-
cence in cancer and aging,” Cell, vol. 130, no. 2, pp. 223–233,
2007.
[34] S. H. Sigal, P. Rajvanshi, and G. R. Gorla, “Partial
hepatectomy-induced polyploidy attenuates hepatocyte repli-
cation and activates cell aging events,” American Journal of
Physiology, vol. 276, no. 5, pp. G1260–G1272, 1999.
[35] W. Brodsky Ya. and I. V. Uryvaeva, “Cell polyploidy: its
relation to tissue growth and function,” International Review
of Cytology, vol. 50, pp. 275–332, 1977.
[36] G. P. Dimri, X. Lee, and G. Basile, “A biomarker that identiﬁes
senescent human cells in culture and in aging skin in vivo,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 92, no. 20, pp. 9363–9367, 1995.
[37] M. Braig, S. Lee, and C. Loddenkemper, “Oncogene-induced
senescence as an initial barrier in lymphoma development,”
Nature, vol. 436, no. 7051, pp. 660–665, 2005.
[38] V. Krizhanovsky, M. Yon, and R. A. Dickins, “Senescence of
activated stellate cells limits liver ﬁbrosis,” Cell, vol. 134, no. 4,
pp. 657–667, 2008.
[39] M. Hoare, T. Das, and G. Alexander, “Ageing, telomeres,
senescence,andliverinjury,”JournalofHepatology,vol.53,no.
5, pp. 950–961, 2010.
[40] J. G. Lunz, S. Contrucci, and K. Ruppert, “Replicative
senescence of biliary epithelial cells precedes bile duct loss in
chronic liver allograft rejection: increased expression of p21
as a disease marker and the inﬂuence of immunosuppressive
drugs,” American Journal of Pathology, vol. 158, no. 4, pp.
1379–1390, 2001.
[41] V. Paradis, N. Youssef, and P. Bedossa, “Replicative senescence
in normal liver, chronic hepatitis C, and hepatocellular
carcinomas,” Human Pathology, vol. 32, no. 3, pp. 327–332,
2001.
[42] S. U. Wiemann, A. Satyanarayana, and M. Tsahuridu, “Hepa-
tocytetelomereshorteningandsenescencearegeneralmarkers
of human liver cirrhosis,” FASEB Journal,v o l .1 6 ,n o .9 ,p p .
935–942, 2002.
[43] R. R. Plentz, Y. N. Park, and A. Lechel, “Telomere shortening
and inactivation of cell cycle checkpoints characterize human
hepatocarcinogenesis,” Hepatology, vol. 45, no. 4,pp. 968–976,
2007.
[44] R. R. Plentz, B. Schlegelberger, and P. Flemming, “Telomere
shortening correlates with increasing aneuploidy of chromo-
some 8 in human hepatocellular carcinoma,” Hepatology, vol.
42, no. 3, pp. 522–526, 2005.
[45] B. Portmann and Y. Nakanuma, “Diseases of the bile ducts,”
in Pathology of the Liver,A .B u r t ,B .C .P o r t m a n n ,a n dL .D .
Ferrell,Eds.,pp.517–581,ChurchillLivingstone,London,UK,
5th edition, 2007.
[46] Y. Nakanuma, Y. Zen, and K. Harada, “Application of a new
histological staging and grading system for primary biliary
cirrhosis to liver biopsy specimens: interobserver agreement,”
Pathology International, vol. 60, no. 3, pp. 167–174, 2010.
[47] M. Serrano and M. A. Blasco, “Putting the stress on senes-
cence,” Current Opinion in Cell Biology, vol. 13, no. 6, pp. 748–
753, 2001.
[48] A. Demetris, “Immunopathology of the human biliary tree,”
in Biliary and Pancreatic Pancreatic Ductal Epithelia, A. Sirica
and D. Longnecker, Eds., pp. 127–180, Marcel Dekker, New
York, NY, USA, 1997.
[49] M.Sasaki,H.Ikeda,Y.Sato,andY.Nakanuma,“Proinﬂamma-
tory cytokine-induced cellular senescence of biliary epithelial
cells is mediated via oxidative stress and activation of ATM
pathway: a culture study,” Free Radical Research, vol. 42, no.
7, pp. 625–632, 2008.
[50] T. A. Roskams, N. D. Theise, and C. Balabaud, “Nomenclature
of the ﬁner branches of the biliary tree: canals, ductules, and
ductular reactions in human livers,” Hepatology, vol. 39, no. 6,
pp. 1739–1745, 2004.International Journal of Hepatology 9
[51] M. Sasaki, H. Ikeda, J. Yamaguchi, M. Miyakoshi, Y. Sato,
and Y. Nakanuma, “Bile ductular cells undergoing cellular
senescence increase inchronicliver diseasesalongwith ﬁbrous
progression,” American Journal of Clinical Pathology, vol. 133,
no. 2, pp. 212–223, 2010.
[52] M. Chiba, M. Sasaki, S. Kitamura, H. Ikeda, Y. Sato, and Y.
Nakanuma, “Participation of bile ductular cells in pathologic
progression of nonalcoholic fatty liver disease,” Journal of
Clinical Pathology, vol. 64, no. 7, pp. 564–570, 2011.
[53] N. Mizushima, “Autophagy: process and function,” Genes and
Development, vol. 21, no. 22, pp. 2861–2873, 2007.
[54] X. M. Yin, W. X. Ding, and W. Gao, “Autophagy in the liver,”
Hepatology, vol. 47, no. 5, pp. 1773–1785, 2008.
[55] B. Levine and G. Kroemer, “Autophagy in the pathogenesis of
disease,” Cell, vol. 132, no. 1, pp. 27–42, 2008.
[56] A. R. J. Young, M. Narita, and M. Ferreira, “Autophagy
mediates the mitotic senescence transition,” Genes and Devel-
opment, vol. 23, no. 7, pp. 798–803, 2009.
[57] Y. Kabeya, N. Mizushima, and T. Ueno, “LC3, a mammalian
homologue of yeast Apg8p, is localized in autophagosome
membranes after processing,” EMBO Journal, vol. 19, no. 21,
pp. 5720–5728, 2000.
[58] E. White and S. W. Lowe, “Eating to exit: autophagy-enabled
senescence revealed,” Genes and Development, vol. 23, no. 7,
pp. 784–787, 2009.
[59] J. Campisi and F. D’Adda di Fagagna, “Cellular senescence:
when bad things happen to good cells,” Nature Reviews
Molecular Cell Biology, vol. 8, no. 9, pp. 729–740, 2007.
[60] J. C. Barrett, S. Hansoul, and D. L. Nicolae, “Genome-wide
association deﬁnes more than 30 distinct susceptibility loci for
Crohn’s disease,” Nature Genetics, vol. 40, no. 8, pp. 955–962,
2008.
[61] V. Men´ endez-Benito and J. Neefjes, “Autophagy in MHC class
II presentation: sampling from within,” Immunity, vol. 26, no.
1, pp. 1–3, 2007.
[62] H. J. Anders and D. O. Schlondorﬀ, “Innate immune receptors
and autophagy: implications for autoimmune kidney injury,”
Kidney International, vol. 78, no. 1, pp. 29–37, 2010.
[63] A. Lleo, P. Invernizzi, and C. Selmi, “Autophagy: highlighting
a novel player in the autoimmunity scenario,” Journal of
Autoimmunity, vol. 29, no. 2-3, pp. 61–68, 2007.
[ 6 4 ]J .B .H a r l e y ,L .A .C r i s w e l l ,a n dC .O .J a c o b ,“ G e n o m e - w i d e
association scan in women with systemic lupus erythematosus
identiﬁes susceptibility variants in ITGAM, PXK, KIAA1542
and other loci,” Nature Genetics, vol. 40, no. 2, pp. 204–210,
2008.
[65] J. W. Han, H. F. Zheng, and Y. Cui, “Genome-wide association
study in a Chinese Han population identiﬁes nine new
susceptibility loci for systemic lupus erythematosus,” Nature
Genetics, vol. 41, no. 11, pp. 1234–1237, 2009.
[66] J. Nedjic, M. Aichinger, J. Emmerich, N. Mizushima, and
L. Klein, “Autophagy in thymic epithelium shapes the T-cell
repertoire and is essential for tolerance,” Nature, vol. 455, no.
7211, pp. 396–400, 2008.
[67] X. Qu, Z. Zou, and Q. Sun, “Autophagy gene-dependent
clearance of apoptotic cells during embryonic development,”
Cell, vol. 128, no. 5, pp. 931–946, 2007.
[68] H. K. Lee, L. M. Mattei, and B. E. Steinberg, “In vivo
requirement for Atg5 in antigen presentation by dendritic
cells,” Immunity, vol. 32, no. 2, pp. 227–239, 2010.
[69] G. Hu and B. J. Barnes, “IRF-5 is a mediator of the death
receptor-induced apoptotic signaling pathway,” Journal of
Biological Chemistry, vol. 284, no. 5, pp. 2767–2777, 2009.
[70] X. Ouyang, H. Negishi, R. Takeda, Y. Fujita, T. Taniguchi,
and K. Honda, “Cooperation between MyD88 and TRIF
pathways in TLR synergy via IRF5 activation,” Biochemical
and Biophysical Research Communications, vol. 354, no. 4, pp.
1045–1051, 2007.
[71] C. Miceli-Richard, E. Comets, P. Loiseau, X. Puechal, E.
Hachulla, and X. Mariette, “Association of an IRF5 gene
functional polymorphism with Sjogren’s syndrome,” Arthritis
and Rheumatism, vol. 56, no. 12, pp. 3989–3994, 2007.
[72] D.Feng,R.C.Stone,andM.L.Eloranta,“Geneticvariantsand
disease-associated factors contribute to enhanced interferon
regulatory factor 5 expression in blood cells of patients with
systemic lupus erythematosus,” Arthritis and Rheumatism, vol.
62, no. 2, pp. 562–573, 2010.
[73] J. C. Acosta, A. Banito, and M. V. Guijarro, “Chemokine
signaling via the CXCR2 receptor reinforces senescence,” Cell,
vol. 133, no. 6, pp. 1006–1018, 2008.
[74] T. Kuilman, C. Michaloglou, and L. C. W. Vredeveld,
“Oncogene-induced senescence relayed by an interleukin-
dependent inﬂammatory network,” Cell, vol. 133, no. 6, pp.
1019–1031, 2008.
[75] N. Wajapeyee, R. W. Serra, X. Zhu, M. Mahalingam, and M.
R.Green,“OncogenicBRAFinducessenescenceandapoptosis
through pathways mediated by the secreted protein IGFBP7,”
Cell, vol. 132, no. 3, pp. 363–374, 2008.
[76] D. N. Shelton, E. Chang, P. S. Whittier, D. Choi, and W. D.
Funk, “Microarray analysis of replicative senescence,” Current
Biology, vol. 9, no. 17, pp. 939–945, 1999.
[77] J.-P. Copp´ e, C. K. Patil, F. Rodier et al., “Senescence-associated
secretory phenotypes reveal cell-nonautonomous functions of
oncogenic RAS and the p53 tumor suppressor,” PLoS Biology,
vol. 6, no. 12, article e301, 2008.
[78] D. Alvaro, M. G. Mancino, and S. Glaser, “Proliferating
cholangiocytes: a neuroendocrine compartment in the dis-
eased liver,” Gastroenterology, vol. 132, no. 1, pp. 415–431,
2007.
[79] S. Shimoda, K. Harada, and H. Niiro, “Biliary epithelial cells
and primary biliary cirrhosis: the role of liver-inﬁltrating
mononuclear cells,” Hepatology, vol. 47, no. 3, pp. 958–965,
2008.
[80] K. Tsuneyama, K. Harada, and M. Yasoshima, “Monocyte
chemotactic protein-1, -2, and -3 are distinctively expressed
in portal tracts and granulomata in primary biliary cirrhosis:
implicationsforpathologenesis,”JournalofPathology,vol.193,
no. 1, pp. 102–109, 2001.
[81] K. Isse, K. Harada, Y. Zen et al., “Fractalkine and CX3CR1 are
involved in the recruitment of intraepithelial lymphocytes of
intrahepatic bile ducts,” Hepatology, vol. 41, no. 3, pp. 506–
516, 2005.
[82] M. Yasoshima, N. Kono, H. Sugawara, K. Katayanagi,
K. Harada, and Y. Nakanuma, “Increased expression of
interleukin-6 and tumor necrosis factor-alpha in pathologic
biliary epithelial cells: in situ and culture study,” Laboratory
Investigation, vol. 78, no. 1, pp. 89–100, 1998.